BGPT: Paper Review: Extracellular Matrix Secretion by Cardiac Fibroblasts

Fuel Your Discoveries

Quick Explanation Copied

Core takeaway

This Circulation Research study uses secretome proteomics to show that miR-29b (more than miR-30c) strongly reshapes cardiac fibroblast extracellular protein output, including fibrosis-linked ECM and growth factors (notably IGF-1 and LIF), and that in vivo miR-29b inhibition increases perivascular fibrosis in pressure overload.

Long Explanation

Paper review (skeptical, evidence-first): “Extracellular Matrix Secretion by Cardiac Fibroblasts: Role of MicroRNA-29b and”

Primary source DOI: 10.1161/CIRCRESAHA.113.302400 (Published Oct 25, 2013)

1) Visual: what the study actually measured

The main experimental “readout” is extracellular secretome composition from cardiac fibroblasts under miRNA perturbations, using LC-MS/MS on conditioned medium, followed by targeted validation (ELISA + luciferase reporters) for selected proteins/growth factors and additional functional assays on cardiomyocytes.

2) Visual: in vivo effect size signals reported

The paper reports that antagomiR-mediated miR-29b inhibition in mice subjected to TAC increases perivascular fibrosis while changes in global systolic function/volumes were not overtly worsened in their analysis.

Confidence note: these are approximate effect sizes (~) reported in the article text; they are still useful for directionality but should not be over-quantified.

3) Visual: miR-29b vs miR-30c—claimed differential impact

The authors conclude that miR-29b has a much stronger impact on the CF extracellular proteome than miR-30c, particularly on ECM/collagens and MMP secretion, while miR-30c shows limited ECM protein effects and distinct (opposite-direction) effects on select growth factors/cytokines.

Skeptical caveat: This chart is intentionally qualitative to avoid fabricating fold-changes not provided in the extracted text. The qualitative framing is still grounded in the paper’s claims about “markedly attenuated” vs “little effect” and opposite regulation of IGF-1/LIF.

4) Mechanism claims: what’s direct vs indirect?

The study explicitly distinguishes direct targets (via 3′-UTR complementarity + functional reporter validation) from indirect effects (proteomics changes that may reflect network-level consequences or pathway effects).

Direct seed-validated (as described)

IGF-1: ELISA/proteomics correlation and 3′-UTR reporter response to miR-29b mimic (decrease of reporter activity for IGF-1 3′-UTR).
LIF: similar reporter/seed validation logic.

Weaker direct evidence (as described)

PTX-3: ELISA/proteomics changes are reported, but the luciferase reporter evidence for direct seed repression is described as not matching the expected seed-region repression behavior.

5) Functional relevance: cardiomyocyte outcomes from CF secretome

The authors test whether miRNA-driven changes in CF conditioned medium alter cardiomyocyte adhesion and cardiomyocyte protein expression markers (α-actinin, cMyBP-C, troponin I), and they report that miR-29b-conditioned medium leads to cardiomyocyte atrophy/protein decreases in their in vitro systems, while miR-30c has different/opposite effects.

6) Critical appraisal (what could mislead, and what would change the conclusion)

6.1 Key methodological strengths

Protein-level secretome readout rather than only mRNA predictions, matching the stated goal to capture coordinated extracellular protein changes.
Multiple validation layers (proteomics → ELISA correlation → luciferase reporter seed tests for selected targets → in vivo antagomiR for at least IGF-1 derepression + fibrosis phenotype).

6.2 Blindspots / uncertainties (skeptical stance)

Seed/target inference isn’t uniform across proteins. PTX-3 shows evidence of protein-level change but not equivalent seed-reporter behavior in their assays, implying indirect regulation or context-specific mechanisms.
Overexpression/antagomiR biology may exceed physiological range. The study’s proteomics effects follow strong manipulations in cultured CF; transfection can saturate processing/binding sites and create stress-dependent network changes. The paper itself flags the possibility that stronger pre-miR effects than anti-miR effects could reflect saturation and stress susceptibility.
Species and model dependency. Cardiac fibrosis is complex; the study uses mouse CF + rat myocytes for cross-talk assays and mouse TAC for in vivo confirmation. Direct translation to human fibrosis requires careful evidence (this is inherently uncertain from this single study).

6.3 What information would disprove or materially revise the main claim?

If miR-29b inhibition in vivo did not produce fibrosis increases under TAC (or fibrosis increases were not accompanied by proteomics-consistent derepression of identified extracellular targets like IGF-1), the causal direction would be weakened.
If the extracellular target set required to reproduce the cardiomyocyte adhesion/atrophy phenotype could not be recovered (e.g., if conditioned media effects persisted without the observed extracellular protein changes), then “secretome-mediated” explanation would be revised.

7) Tables: concise mapping of reported target validation

Protein	Reported miR-29b direction (secretome/ELISA)	Seed/reporter support described	Interpretation in paper
IGF-1	Suppressed by pre-miR-29b; increased by anti-miR-29b	3′-UTR luciferase decreased by miR-29b mimic; seed complementarity described	Direct target (in their validation logic)
LIF	Suppressed by pre-miR-29b; increased by anti-miR-29b	3′-UTR luciferase decreased by miR-29b mimic; seed complementarity described	Direct target (in their validation logic)
PTX-3	Suppressed by pre-miR-29b; increased by anti-miR-29b (ELISA/proteomics correlation)	Paper reports no decrease of PTX-3 3′-UTR reporter activity by miR-29b	Directness uncertain → consistent with indirect regulation in their framing

8) BGPT next steps: targeted questions you can ask

Want to go beyond this review? Use these specialized query buttons to get mechanistic maps, counterfactuals, and data extraction workflows.

This agent can iteratively extract additional quantitative details from the provided tables/figures and build tighter plots.

Feedback:

Updated: April 17, 2026